Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Nanoparticle albumin bound paclitaxel

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,016Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 20Abraxane

    02 1Abraxane - BMS

    03 1Abraxane - Celgene

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    DCAT Week
    Not Confirmed

    Bristol Myers Squibb

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,247

    2019 Revenue in Millions : 1,086

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    Japan
    arrow
    DCAT Week
    Not Confirmed

    Otsuka

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 292

    2019 Revenue in Millions : 275

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    DCAT Week
    Not Confirmed

    Bristol Myers Squibb

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,181

    2020 Revenue in Millions : 1,247

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    PBP World Meeting
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    PBP World Meeting
    Not Confirmed

    Beigene

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 0

    2020 Revenue in Millions : 19

    Growth (%) : -100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    Japan
    arrow
    DCAT Week
    Not Confirmed

    Otsuka

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 242

    2020 Revenue in Millions : 280

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    DCAT Week
    Not Confirmed

    Bristol Myers Squibb

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 811

    2021 Revenue in Millions : 1,181

    Growth (%) : -31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    Japan
    arrow
    DCAT Week
    Not Confirmed

    Otsuka

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 153

    2021 Revenue in Millions : 242

    Growth (%) : -37

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    DCAT Week
    Not Confirmed

    Bristol Myers Squibb

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,004

    2022 Revenue in Millions : 811

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    Japan
    arrow
    DCAT Week
    Not Confirmed

    Otsuka

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 213

    2022 Revenue in Millions : 153

    Growth (%) : 58

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Abraxane

    Paclitaxel Protein Bound

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Abraxane

    U.S.A
    arrow
    DCAT Week
    Not Confirmed

    Bristol Myers Squibb

    Paclitaxel Protein Bound

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 875

    2023 Revenue in Millions : 1,004

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.